Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough. Trevi Therapeutics, Inc. has a license agreement with Keenova Therapeutics plc to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. Trevi Therapeutics, Inc. was incorporated in 2011 and is headquartered in New Haven, Connecticut. Show more

195 Church Street, New Haven, CT, 06510, United States

Biotechnology

Healthcare

Market Cap

1.455B

52 Wk Range

$4.85 - $14.39

Previous Close

$11.80

Open

$11.69

Volume

1,429,522

Day Range

$11.01 - $11.97

Enterprise Value

1.175B

Cash

194.9M

Avg Qtr Burn

-10.88M

Insider Ownership

0.68%

Institutional Own.

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Haduvio (oral nalbuphine ER) Details Idiopathic pulmonary fibrosis chronic cough	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Haduvio/Nalbuphine (NAL ER) (Kappa Mu Modulator) Details Non-IPF ILD-Related Chronic Cough	Phase 2b Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Haduvio (oral nalbuphine ER) Copy Details Refractory Chronic Cough	Phase 2b Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.